小细胞肺癌患者血清及胸水中ProGRP表达水平及临床意义
|
摘要
目的探讨小细胞肺癌患者血清及胸水中胃泌素释放肽前体(ProGRP)表达水平及临床意义。方法选择本院2014年1月至2016年12月收治的200例小细胞肺癌患者为研究对象(观察组),另选择同期本院收治肺部炎症患者200例作为对照组,分别采用罗氏电化学发光自动分析仪检测血清和胸水ProGRP水平。结果观察组血清及胸水ProGRP水平均高于对照组(P<0.05),且观察组胸水ProGRP水平高于血清ProGRP水平(P<0.05);观察组广泛期血清及胸水ProGRP水平均明显高于局限期(P<0.05),且观察组各期胸水ProGRP水平高于血清ProGRP水平(P<0.05);观察组血清ProGRP检测灵敏度低于胸水ProGRP检测(P<0.05);治疗后缓解期、好转期胸水ProGRP水平降低(P<0.05),进展期胸水ProGRP水平升高(P<0.05),胸水ProGRP水平:缓解期<好转期<进展期(P<0.05)。结论小细胞肺癌患者胸水中ProGRP表达水平高于血清中ProGRP表达水平,对小细胞肺癌诊断、分期判断及预后均有较高临床价值。
Objective To investigate the expression level and clinical significance of pro-gastrin-releasing peptide(ProGRP) in serum and pleural effusion of patients with small cell lung cancer. Methods A total of 200 patients with small cell lung cancer admitted to the hospital from January2014 to December 2016 were enrolled as study objects(observation group). Another 200 patients with pulmonary inflammation in the hospital during same period were selected as the control group. Roche automatic electrochemiluminescence analyzer was performed to detect ProGRP levels in serum and pleural effusion. Results The ProGRP levels in serum and pleural effusion of the observation group were higher than those of the control group(P<0.05). The ProGRP level in pleural effusion of the observation group was higher than that in the serum(P<0.05). The ProGRP levels in serum and pleural effusion during extensive stage in the observation group were significantly higher than those during limited stage. The ProGRP levels in pleural effusion during all stages of the observation group were higher than those in the serum(P<0.05). The sensitivity for detecting serum ProGRP in the observation group was lower than that for detecting pleural effusion ProGRP(P<0.05). The levels of ProGRP in pleural effusion during remission period and improvement period were decreased after treatment(P<0.05), while the levels of ProGRP in pleural effusion during advanced stage increased(P<0.05). The level of ProGRP in pleural effusion during remission period was the least, followed by improvement period and advanced period(P<0.05). Conclusion The expression level of ProGRP in pleural effusion of patients with small cell lung cancer is higher than that in serum, which has high clinical value for the diagnosis, staging judging and prognosis of small cell lung cancer.
Objective To investigate the expression level and clinical significance of pro-gastrin-releasing peptide(ProGRP) in serum and pleural effusion of patients with small cell lung cancer. Methods A total of 200 patients with small cell lung cancer admitted to the hospital from January2014 to December 2016 were enrolled as study objects(observation group). Another 200 patients with pulmonary inflammation in the hospital during same period were selected as the control group. Roche automatic electrochemiluminescence analyzer was performed to detect ProGRP levels in serum and pleural effusion. Results The ProGRP levels in serum and pleural effusion of the observation group were higher than those of the control group(P<0.05). The ProGRP level in pleural effusion of the observation group was higher than that in the serum(P<0.05). The ProGRP levels in serum and pleural effusion during extensive stage in the observation group were significantly higher than those during limited stage. The ProGRP levels in pleural effusion during all stages of the observation group were higher than those in the serum(P<0.05). The sensitivity for detecting serum ProGRP in the observation group was lower than that for detecting pleural effusion ProGRP(P<0.05). The levels of ProGRP in pleural effusion during remission period and improvement period were decreased after treatment(P<0.05), while the levels of ProGRP in pleural effusion during advanced stage increased(P<0.05). The level of ProGRP in pleural effusion during remission period was the least, followed by improvement period and advanced period(P<0.05). Conclusion The expression level of ProGRP in pleural effusion of patients with small cell lung cancer is higher than that in serum, which has high clinical value for the diagnosis, staging judging and prognosis of small cell lung cancer.
引文
[1]郑佳彬,李冰雪,程倩雯,等.非小细胞肺癌患者术后中医药治疗研究进展[J].中国肿瘤临床与康复,2017,24(1):125-128.
[2]丁一波,傅忠星,王烨菁,等.2004-2011年上海市卢湾区社区人群肺癌的发病和死亡资料分析[J].中国临床医学,2016,23(5):602-606.
[3]袁建伟.肿瘤标志物的参考区间在肿瘤患者疾病诊断中的临床价值评估[J].中国药物与临床,2016,16(7):1076-1077.
[4]孙书美,李飞,徐友文,等.外周血胃泌素释放肽前体和神经元特异性烯醇化酶在小细胞肺癌中的应用[J].中国卫生检验杂志,2016,26(9):1283-1284.
[5]Evans WK,Feld R,Osoba D,et al.VP16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer[J].Cancer,2015,53(7):1461-1466.
[6]蒋日成,李凯.小细胞肺癌免疫治疗的临床研究进展[J].中国肿瘤临床,2016,43(24):1106-1111.
[7]聂婷婷,王迎难,张家祺,等.小细胞肺癌中胃泌素释放肽前体水平变化及其相关性研究[J].临床内科杂志,2015,32(4):238-241.
[8]王静静,陈梅莉,钱震东,等.小细胞肺癌患者胃泌素释放肽前体表达的临床意义[J].实用医学杂志,2016,32(11):1784-1787.
[9]黄梅香,梁艺华,任宁毅,等.胃泌素释放肽前体在小细胞肺癌诊断及治疗中应用[J].现代仪器与医疗,2015,21(3):82-84.
[10]吴培生,徐爱晖.胃泌素释放肽前体在小细胞肺癌中的表达水平及其意义[J].中国全科医学,2014,7(32):3885-3887.
[2]丁一波,傅忠星,王烨菁,等.2004-2011年上海市卢湾区社区人群肺癌的发病和死亡资料分析[J].中国临床医学,2016,23(5):602-606.
[3]袁建伟.肿瘤标志物的参考区间在肿瘤患者疾病诊断中的临床价值评估[J].中国药物与临床,2016,16(7):1076-1077.
[4]孙书美,李飞,徐友文,等.外周血胃泌素释放肽前体和神经元特异性烯醇化酶在小细胞肺癌中的应用[J].中国卫生检验杂志,2016,26(9):1283-1284.
[5]Evans WK,Feld R,Osoba D,et al.VP16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer[J].Cancer,2015,53(7):1461-1466.
[6]蒋日成,李凯.小细胞肺癌免疫治疗的临床研究进展[J].中国肿瘤临床,2016,43(24):1106-1111.
[7]聂婷婷,王迎难,张家祺,等.小细胞肺癌中胃泌素释放肽前体水平变化及其相关性研究[J].临床内科杂志,2015,32(4):238-241.
[8]王静静,陈梅莉,钱震东,等.小细胞肺癌患者胃泌素释放肽前体表达的临床意义[J].实用医学杂志,2016,32(11):1784-1787.
[9]黄梅香,梁艺华,任宁毅,等.胃泌素释放肽前体在小细胞肺癌诊断及治疗中应用[J].现代仪器与医疗,2015,21(3):82-84.
[10]吴培生,徐爱晖.胃泌素释放肽前体在小细胞肺癌中的表达水平及其意义[J].中国全科医学,2014,7(32):3885-3887.